Boston, MA - A new study confirms that the presence of left ventricular outflow tract obstruction, occurring in about a quarter of patients with hypertrophic cardiomyopathy (HCM), is a "strong, ...

Boston, MA - A nonsurgical procedure to reduce the interventricular septum in patients with hypertrophic cardiomyopathy (HCM) produces sustained improvements in exercise capacity and reductions in ...

Background. A 61-year-old man presented with shortness of breath and chest pain on exertion. He had been diagnosed as having hiatus hernia 2 years previously and was taking proton-pump inhibitors as ...

Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Patients with obstructive hypertrophic cardiomyopathy who were treated with mavacamten for 1 year ...

Even though mortality and hospitalization rates have improved, the quality of life for those living with hypertrophic cardiomyopathy (HCM) can be compromised with limiting symptoms such as exertional ...

For patients with obstructive HCM in the PIONEER-OLE study, mavacamten was shown to improve patients' symptoms, reduce LVOT obstruction, and essentially improve myocardial efficiency, said Stephen ...

Please provide your email address to receive an email when new articles are posted on . Cardiac myosin inhibitors are now recommended as therapy for certain patients with obstructive hypertrophic ...

Background A 42-year-old woman with a 20-year history of obstructive hypertrophic cardiomyopathy was referred for alcohol septal ablation following a worsening of symptoms, which had persisted despite ...

Credit: Getty Images HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C. Hypertrophic cardiomyopathy (HCM) ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for mavacamten, ...

The American Heart Association (AHA) and the American College of Cardiology (ACC), with the support of several other professional societies, have released updated guidelines for the management of ...